

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF
04 APR 12 1

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) -All Filers Are Required to Complete This Page

1. Registrant Name Capitol Health Group, LLC			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1100 New York Avenue, NW Suite 200M City Washington State/Zip (or Country) DC 20005-6104			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Layna Peltier	Telephone 202-216-2255	E-mail (optional) Layna@caphg.com	5. Senate ID #
7. Client Name <input type="checkbox"/> Self Pfizer			6. House ID # 35502011


TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobbyi

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$40,000.00</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of:</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033 the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>

Signature  _____ Date 2/6/2004

Printed Name and Title Layna Peltier - Principal _____ Pag

Registrant Name: Capitol Health Group, LLC

Client Name: Pfizer

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

**H.R.1 , Medicare Prescription Drug and Modernization Act of 2003,
H.R.2427 , Pharmaceutical Market Access Act of 2003,
S.1 , Prescription Drug and Medicare Improvement Act of 2003,**

17. House(s) of Congress and Federal agencies contacted

Check if None

**Department of Health & Human Services
Executive Office of the President
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bromberg, Michael	
Coughlin, Shawn	
Jenning, Steve	
Peltier, Layna	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date 2/6/2004

Printed Name and Title Layna Peltier - Principal Page _____

Registrant Name: Capitol Health Group, LLC

Client Name: Pfizer

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

**H.R.1 , Medicare Prescription Drug and Modernization Act of 2003,
H.R.2427 , Pharmaceutical Market Access Act of 2003,
S.1 , Prescription Drug and Medicare Improvement Act of 2003,**

17. House(s) of Congress and Federal agencies contacted

Check if None

**Department of Health & Human Services
Executive Office of the President
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bromberg, Michael	
Coughlin, Shawn	
Jenning, Steve	
Peltier, Layna	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date 2/6/2004

Printed Name and Title Layna Peltier - Principal _____ Pag